Dysregulation of Receptor for Advanced Glycation End Products (RAGE) Expression as a Biomarker of Keratoconus

Valentin Navel, Jean Malecaze, Corinne Belville, Hélène Choltus, Fanny Henrioux, Frédéric Dutheil, François Malecaze, Frédéric Chiambaretta, Loïc Blanchon, and Vincent Sapin

1University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Ophthalmology, F-63000 Clermont-Ferrand, France
2Translational Approach to Epithelial Injury and Repair Team, University of Clermont Auvergne, CNRS UMR 6293, INSERM U1103, Genetic Reproduction and Development Laboratory (GReD), F-63000 Clermont-Ferrand, France
3University of Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000 Clermont-Ferrand, France
4Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France
5Department of Biochemistry and Molecular Genetic, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France

Correspondence should be addressed to Valentin Navel; valentin.navel@hotmail.fr

Received 17 August 2021; Revised 11 December 2021; Accepted 3 January 2022; Published 15 January 2022

Copyright © 2022 Valentin Navel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Because of the implications of Receptor for Advanced Glycation End Products (RAGE) in keratoconus (KC), we describe a differential expression of RAGE transcripts and proteins in corneal tissues and tears of KC and healthy patients.

Methods. Using a case-controlled study, corneal epitheliums and tears of KC and healthy subjects were obtained during corneal collagen cross-linking and photorefractive keratectomy (PKR) and during usual consultations. Quantitative reverse transcription (RT-qPCR) and Western-Blot were performed to analyze RAGE transcripts and proteins’ expression in corneal tissues and tears.

Results. One hundred and six patients were included in this study. The characteristics of the patients were as follows: 56 KC (25 corneal epithelium and 31 tears) and 50 control subjects (25 corneal epithelium and 25 tears). Transcripts of RAGE, HMGB1, and S100 family ligands were quantified by RT-qPCR, identifying a significantly higher expression of RAGE and HMGB1 in the healthy group than in the KC group (p = 0.03 and 0.04, respectively). Western Blot showed a significantly higher fl-RAGE expression in KC corneal epithelium than control (p < 0.001) and lower s-RAGE expression in KC tears than control (p = 0.04).

Conclusions. Linked with the inflammatory process occurring in KC pathophysiology, we propose for the first time that the RAGE expression (total and truncated forms of receptor and ligands) in KC corneal tissues and tear samples provides viable biomarkers.

1. Introduction

Keratoconus (KC) is a progressive vision-threatening corneal disease classically beginning in the second decade of life, causing deformation of the structure of the cornea [1–4]. Because the regular corneal curvature has a predominant role in refraction and quality of vision [5], this disease causes a visual impairment despite therapeutic strategies involving the use of rigid contact lenses [6], corneal collagen cross-linking [7, 8], refractive surgeries [9], or advances in corneal grafting [10, 11]. The prevalence of KC is approximately 5.3/2000 in the general population [12], with certain ethnic groups, such as Asians being more at risk [13]. Well-known environmental factor such as eye rubbing [14, 15] or atopy [16, 17] also increases the frequency. There is some evidence for genetic transmission [18–20]. However, the physiopathology of this disease is still poorly understood, and many questions persist in relation to triggering and
progression of ectasia. To our knowledge, there are no biomarkers clearly described in the ocular surface (e.g., corneal tissues or tears) of KC. If KC was initially defined as a non-inflammatory corneal disease, several studies during the past decade have described an inflammatory process in corneal tissues and tears. In fact, pro-inflammatory cytokines (IL-1, IL-6, TNF-α, and TGF-β), oxidative stress, or degradation of collagens by metalloproteinases (MMP-1, MMP-3, and MMP-9) has been implicated in keratoconus pathophysiology [3, 21–25].

Receptor for Advanced Glycation End Products (RAGE) is a multiligand transmembrane receptor (member of the immunoglobulin superfamily) implicated in inflammation and cell migration processes [26–28]. The pre-mRNA of RAGE can be subjected to alternative splicing causing truncated RAGE isoforms from the same gene: full-length RAGE (fl-RAGE) and soluble forms RAGE (s-RAGE) including endogenous secretory RAGE (es-RAGE) and cleaved RAGE (c-RAGE), with molecular weights of 35–55 kD varying between isoforms, cellular types, and tissues. fl-RAGE is a transmembrane receptor (able to transduct the signal) whereas s-RAGE corresponds to soluble truncated isoforms of fl-RAGE, comprising an extracellular domain, and plays a role as a decoy to prevent ligands from interacting with fl-RAGE receptors [29–31] (Figure 1). Expression of RAGE, described in several human tissues, is upregulated in response to its natural and historical ligand, i.e., advanced glycation end products (AGEs), but also HMGB1 and S100 proteins that are well-known in aseptic inflammation and oxidative stress of diabetes patients, atherosclerosis, pulmonary and autoimmune diseases, cancer, and chronic neurodegenerative like Alzheimer’s disease [30–34]. In ophthalmology, we recently demonstrated the implications of RAGE in the first steps of corneal epithelial wound healing [35].

In addition, previous studies described the role of RAGE in primary open-angle glaucoma [36], diabetic retinopathy [37–39], age-related macular degeneration [40], endothelial Fuchs’s dystrophy [41], cataract, and posterior capsule opacification [42] or pterygium [43]. However, to our knowledge, there is no description in KC. Therefore, the purpose of this study was to highlight the role of the RAGE pathway in the cornea and tears of KC compared to healthy patients. A further aim was to describe a putative candidate viable biomarker in the ocular surface of KC.

2. Material and Methods

2.1. Subjects. One hundred and six subjects, over 18 years of age, were enrolled in the study. Fifty healthy subjects and 56 patients with clinically and topographic KC were considered for the study. The exclusion criteria were ocular surgery performed during the past 3 months, ocular allergy or any ocular disease, dry eye syndrome, any systemic disease, and local or systemic medication (anti-inflammatory) that could interfere with the interpretation of the results. The diagnosis of KC was performed by clinical examination (objective and subjective refraction, slit lamp with fluorescein testing, and tonometry) and topographic evaluation using a Pentacam (Oculus Optikgeräte GmbH, Wetzlar, Germany). The research received approval from the University Hospital Ethics Committees and was conducted in accordance with the recommendations of the Declaration of Helsinki on Biomedical Research Involving Human Subjects. Prior to any data collection, all patients were orally informed about the nature of the study and the working hypothesis and therapeutic education concerning keratoconus. Signed informed consent was obtained from all patients prior to collection of tears or epithelium samples.

2.2. Corneal and Tear Sampling. Corneal epithelia of KC were obtained during surgical intervention of collagen crosslinking with UVA irradiation (A-CXL) and corneal de-epithelialization (Epi-Off technique). After topical anesthesia using one drop of Oxybuprocaine (Oxybuprocaine THEA 1.6 mg/0.4 ml, single-dose eye drop), we used a disposable scarifier to de-epithelialize 6.5 to 8.5 mm of cornea. Epithelial samples were stored at -80°C in 1.5 ml Eppendorf tubes. The same protocol was used for healthy subjects undergoing PRK surgery.

Tear samples were collected without topical anesthesia, using calibrated 20 μl glass micropipettes (BLAUBRAND intraMark, Wertheim, Germany), from the inferior temporal tear meniscus, taking care to minimize the irritation of the ocular surface. The samples (from 5 to 8 μl per eye) were placed in 0.2 ml Eppendorf tubes using a pipetting aid for capillaries (HIRSCHMANN Laborgeräte GmbH & Co., Eberstadt, Germany) and stored at -80°C.

2.3. RNA Extraction and Reverse Transcriptase Quantitative PCR Assays. Total RNA was extracted from corneal epithelium using RNeasy® Mini Kit (Qiagen, 74106). The RNA concentration was determined by spectrophotometry at 260 nm with the Denovix DS-11 FX NanoDrop. The cDNA was synthetized from 1 μg of RNA using oligo-(dT) primers (Promega, C1101), 10 mM dNTP (Invitrogen, 10297-018), SuperScript IV Reverse Transcriptase (Invitrogen, 18090050), and rRNasin® RNase Inhibitor (Promega, N2515). The reaction mixture (20 μl) was incubated at 65°C for 5 min, 50°C for 10 min, 80°C for 10 min, and, after addition of RNase H (Promega, M4281), 37°C for 20 min. The primer sequences used for classic or quantitative RT-PCR are indicated in Table 1. Recombinant Taq Polymerase (Invitrogen, 10342-020) and 5 mM dNTP (Invitrogen, 10297-018) were used. The reaction mixture (50 μl) was incubated for 10 min at 95°C, followed by 35 amplification cycles—comprising 45 sec at 94°C, 45 sec at the annealing temperature specific to each primer pair, indicated in Table 1, and 45 sec at 72°C and terminated by 10 min at 72°C. A negative control for ampiclon contamination was set up using a complete PCR mix without cDNA. Quantitative PCR reactions were performed using LightCycler® 480 SYBR Green I Master (Roche, 04887352001). We applied the following program on the LightCycler® 480 Instrument II (Roche): 10 min at 95°C, followed by 45 amplification cycles comprising 10 sec at 95°C, 10 sec at the annealing temperature specific to each primer pair, indicated in Table 1, and 15 sec at 72°C. PCR reactions were assessed using Taq
DNA polymerase (Thermo Fisher Scientific, EP0405). We applied the following procedure: 56°C for hybridization, 5 min at 95°C followed by 35 amplification cycles—comprising 45 s at 94°C, 45 sec at the annealing temperature specific to each primer pair, indicated in Table 1, and 45 sec at 72°C and terminated by 10 min at 72°C. Results were analyzed on a 2% agarose gel. (Figure 2) Quantification of two housekeeping genes, RPLP0 and RPS17, and transcripts was

Table 1: Forward and reverse primer sequences used for RT-PCR and RT-qPCR. These primer sequences were used in order to amplify human cDNAs of indicated genes obtained after reverse transcription of total mRNAs, extracted from the corneal epithelium of keratoconus and healthy subjects.

| Gene          | Forward (F) | Reverse (R) | Product size (bp) | Hybridization temperature (°C) |
|---------------|-------------|-------------|-------------------|-------------------------------|
| Total RAGE    | TGTGCTGATCCTCCTGAGA | CGAGGAGGGCGCAACTGCA | 139               | 61                           |
| es/fl-RAGE    | TGTCAGCATCAGCATCAGC | TCCTGTTTTCTGGGCG | fl-RAGE: 195       | es-RAGE: 150                 |
| hsRPLP0       | AGGACTTTAGGTATCACCAC | TATCACAGAGAAAACCTGCA | 219               | 61                           |
| hsRPS17       | TGCGAGGAGATCGCCATTAC | AAGGCTGAGACCTCAGGAAAC | 169               | 61                           |
| hsHMGB1       | ACCTATATCCCTCCTAGAGGGAG | TTTGGGGCCGATCAGGAC | 109               | 61                           |
| hsS100A8      | TAAAGGGGAAATTTCATTGCCTG | GTTAACTGCACCATCAGTGTTG | 137               | 61                           |
| hsS100B       | AAGGGGAGGGAGAAGGACACA | TCCTGGAAGTACATGCAGG | 159               | 61                           |
performed for all samples as an internal control of the amount and quality of cDNA. These two genes were giving the same results when used separately to standardize. Standard curves were used to quantify the number of amplified transcripts. The results are given as the ratio between the amount of each transcript of interest and the geometric mean of these two housekeeping genes (RPLP0 and RPS17) as recommended by the MIQE guidelines. All experiments were performed in triplicate.

2.4. Protein Extraction and Quantification. The corneal epithelium was, respectively, lysed with either 500 μl or 250 μl RIPA buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, and 0.1% SDS), supplemented with 10% Protease inhibitor cocktail (Roche, 04693159001). For the tissues, a preliminary disruption step was performed using ceramic beads (Precellys, KT03961-1-009.2) and a tissue lyser (Qiagen) (three lysing steps during 30 sec). Samples were then vortex-mixed for 5 sec and kept on ice for 10 min, one in three occasions. After centrifugation (5 min, 8000 rpm), supernatants were collected. The Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, 23225) was used to measure the protein concentration according to the manufacturer’s guidelines.

2.5. Western Blot Assays. Forty micrograms of proteins were separated a 4-15% Mini-PROTEAN™ TGX Stain-Free™ Protein gel (Bio-Rad) and transferred to nitrocellulose membranes (Bio-Rad, 1704271) using the Trans-Blot® Turbo™ Transfer System (Bio-Rad). After saturation with 5% skimmed-milk in 1X Tris-Buffered Saline (TBS) buffer (blocking buffer) for 2H, membranes were incubated with primary antibody, anti-RAGE polyclonal goat IgG (1:5000 dilution in blocking buffer supplemented with 0.1% Tween-20) (Biotéchnue, R&D Systems France, AF1179), overnight at 4°C. Membranes were washed three times for 10 min with 1X TBS-0.1% Tween-20 (TBST) and incubated with a 1:5000 dilution of peroxidase-conjugated polyclonal anti-IgG goat (Abliance, B12403) for 2h. Blots were washed with TBST on three occasions for 10 min, rinsed with 1X TBS, and developed with the Clarity Max™ Western ECL Blotting Substrates (Bio-Rad, 1705062) according to the manufacturer’s protocols. The All Blue Standard (Bio-Rad, 161-0373) was used as a protein ladder. The relative intensities of protein bands were analyzed using Image Lab™ software (BIO-RAD), and the results were presented as a ratio between the protein of interest and the total protein on the same blot. The use of stain-free imaging allows for the normalization of bands to the total protein on a blot, without requesting the use of housekeeping proteins or stripping and reprobing.

2.6. Statistical Analysis. All data were analyzed using the GraphPad Prism Program version 5.02. When the distribution of samples in each group respected the normal distribution, we used the parametric t-tests to compare two independent groups. When the distribution of samples did not respect a Gaussian distribution or was too small (n < 15), we used a nonparametric Mann–Whitney test to compare two independent groups. When more than two groups were compared, the nonparametric Kruskal–Wallis test was applied, followed by multiple comparison with Dunn’s correction. In all cases, a p value < 0.05 was considered statistically significant.

3. Results

3.1. Clinical Features. One hundred and six patients were included in the study: 56 KC (25 corneal epithelium and 31 tears) and 50 healthy subjects (25 corneal epithelium and 25 tears). In the KC group, males represented 77.1%, with a mean age of 26.8 ± 8.5 years. KC rubbed eyes in 69.9%, with corneal opacity in 7.2%. In Amsler-Krumeich classification, grade 1, grade 2, grade 3, and grade 4 represented 22.9%, 45.8%, 9.6%, and 12.1%, respectively. In addition, forme fruste keratoconus represented 9.6%. In the control group, males represented 70.6%, with a mean age of 30.6 ± 8.1 years. No age-related or sex-related statistical differences were detected between the groups (p = 0.2). Statistical analysis stratified by age, gender, and KC severity did not reveal significant results (data not shown). More details of clinical and topographic features in each group are presented in Table 2.

3.2. Transcript Expression Levels of RAGE Isoforms and Ligands in KC and Healthy Epithelium. The mRNAs were quantified in corneal samples for RAGE, HMGB1, and S100 family ligands and normalized with the geometric mean of two housekeeping genes (RPLP0 and RPS17) as recommended by the MIQE guidelines. All experiments were performed in triplicate.

**Figure 2:** Amplification of total RAGE and its two principal isoforms (fl-RAGE and es-RAGE) by RT-qPCR. Numbers represent exons; the green arrows involve the forward (F) and reverse (R) transcriptions.
| Samples          | Population (N) | Age (years) | Sex (% men) | Eye rubbing (%) | Corneal opacity (%) | BCVA (logMar) | Km (D) | Kmax (D) | Astigmatism (D) | Thinnest P (μm) | Suspect (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) |
|-----------------|----------------|-------------|-------------|-----------------|---------------------|---------------|--------|----------|-----------------|----------------|-------------|--------------|--------------|--------------|--------------|
| Keratoconus     |                |             |             |                 |                     |               |        |          |                 |                |             |              |              |              |              |
| Corneal epithelium | 25             | 24.3 (8.6)  | 78.8        | 69.7            | 3.0                 | 0.23 (0.23)   | 45.8 (2.4) | 56.9 (8.3) | 1.33 (1.63)     | 476.2 (45.7)   | 0.0          | 30.3         | 57.6         | 6.1          | 6.7          |
| Tears           | 31             | 28.5 (8.1)  | 72.1        | 70.2            | 10.0                | 0.20 (0.25)   | 48.6 (4.2) | 51.3 (4.7) | 6.50 (2.12)     | 453.5 (72.2)   | 16.0         | 18.0         | 38.0         | 12.0         | 16.0         |
| Total           | 56             | 26.8 (8.5)  | 77.1        | 69.9            | 7.2                 | 0.22 (0.24)   | 47.2 (3.5) | 51.3 (4.7) | 4.13 (2.17)     | 462.5 (63.7)   | 9.6          | 22.9         | 45.8         | 9.6          | 12.1         |
| Normal          |                |             |             |                 |                     |               |        |          |                 |                |             |              |              |              |              |
| Corneal epithelium | 25             | 32.4 (6.4)  | 65.4        | 32.6            | 0.0                 | 0.0           | —      | —        | —               | —              | —           | —            | —            | —            | —            |
| Tears           | 25             | 28.7 (9.8)  | 75.8        | 26.4            | 0.0                 | 0.0           | —      | —        | —               | —              | —           | —            | —            | —            | —            |
| Total           | 50             | 30.6 (8.1)  | 70.6        | 29.6            | 0.0                 | 0.0           | —      | —        | —               | —              | —           | —            | —            | —            | —            |

Values are expressed as the mean (SD). BCVA: Best-Corrected Visual Acuity; D: Dioptr.
lower es-RAGE expression in KC than control whereas there were no differences in fl-RAGE expression ($p = 0.03$).

3.3. Protein Expression Levels of RAGE Isoforms and Ligands in KC and Healthy Epithelium and Tears. fl-RAGE (transmembrane forms of RAGE) proteins were quantified in the corneal epithelium of KC and control. Quantification of the attempted band (molecular weight around 45-50 kD) showed a higher expression of fl-RAGE in the KC group than in the control group ($p < 0.001$) (Figure 4(a)). The s-RAGE (soluble forms of RAGE, decoy of fl-RAGE involving anti-inflammatory response) proteins were also quantified in tears of KC and compared with controls. Using the quantification of the attempted band (molecular weight around 30-35 kD) corresponding to s-RAGE, we established that the concentration of s-RAGE in tears was significantly higher in the normal group than in the KC group ($p = 0.04$). (Figure 4(b)).

4. Discussion

Keratoconus has been classically described as a noninflammatory corneal ectatic disorder. However, recent evidence suggests a possible role of inflammation in the pathogenesis of KC. Indeed, several articles have described an upregulation of proinflammatory cytokines, oxidative stress mediators, and enzymes in KC, without evidence in relation to biomarkers. The RAGE transmembrane receptor has been implicated in aseptic inflammation by reaction with AGEs, actors well-known in diabetes and cardiovascular disease. We describe here, for the first time in cornea and tears of KC, the implication of the RAGE-inflammatory pathway, with potential use of the related findings as potential biomarkers for this pathology.

4.1. Keratoconus: An Aseptic Inflammatory Disease? KC was initially admitted to be a noninflammatory disease without cellular infiltration and vascularisation [2]. In the last few decades, many theories have been proposed for the pathogenesis of keratoconus such as incorrect development of cornea, genetic mutations, enzymes released by degeneration cells, and collagen disruption ([44–46]; Yaron S. [47]). Interestingly, extracellular matrix degradation is involved in the production of inflammatory cytokines and enzymes, and vice versa. Proinflammatory cytokines (IL-1, IL-6, TNF-$\alpha$, and TGF-$\beta$) and enzymes, involved in degradation of collagen such as metalloproteases (MMP-1, MMP-3, and MMP-9), were described to be upregulated in KC when looking at tears and corneal samples [3, 21, 24, 25]. These proinflammatory cytokines seem to play a role in the protease cascade, along with the plasmin pathway, cyclooxygenase, and metalloproteinases, which may explain the observed changes in the extracellular matrix [48]. Considering that the production of MMPs is regulated by IL-1, IL-6, and IL-7 and that

![Figure 3: Transcript expression levels (mRNA) of total RAGE and its two principal isoforms (fl-RAGE and es-RAGE) and ligands in KC (25 corneal epithelium) and healthy subjects (25 corneal epithelium). RT-qPCR were performed to identify total RAGE isoforms (a) and his three major ligands (HMGB1 (b), S100A8 (c), and S100B (d)). In addition, we described the ratio between fl-RAGE (e) (transmembrane functional receptor responsible of inflammatory signaling) and es-RAGE (f) (soluble form of RAGE with an action of decoy, produced by alternative splicing) (g). Quantification of two housekeeping genes, RPLP0 and RPS17, and transcripts was performed for all samples as an internal control of the amount and quality of cDNA. The results are given as the ratio between the amount of each transcript of interest and the geometric mean of these two housekeeping genes (RPLP0 and RPS17) transcripts. * $p < 0.05$; ** $p < 0.01$.](image)
TNF-\(\alpha\) increases MMP-1, MMP-3, and MMP-9, it was proposed that there is an inflammatory vicious circle established at the onset or during the progression of ectasia. In addition, evidence-based data showed that oxidative stress imbalance (in tears, cornea, aqueous humour, and blood) seemed to be a central process in the pathophysiology of KC [23]. Therefore, it appears that inflammation is clearly an integral part of the complex pathophysiology of KC.

4.2. RAGE: A Proinflammatory Pathway. RAGE is a glycoprotein transmembrane receptor binding AGEs or Damage-Associated Molecular Patterns (DAMPs also called alarmins): HMGB1/amphoterin family, S100/calgranulin family. RAGE is involved in various inflammatory processes like diabetic complications, chronic inflammatory diseases, atherosclerosis, and chronic neurodegenerative disease such as Alzheimer’s disease [49]. A variety of tissues and cells express this pattern recognition receptor: vascular endothelial, bronchial, and pulmonary cells, vascular smooth muscle cells, neurons, and many others [29, 31]. The involvement of the RAGE pathway in corneal epithelial wound healing, as well as diseases of conjunctiva and retina and trabecular meshwork, has been demonstrated previously [35–41, 43]. The activation of fl-RAGE stimulates NF-\(\kappa\)B, a transcription factor residing at the inactive state in the cytosol of cells, which can modulate the expression of proinflammatory cytokines, vasoconstrictive and prothrombotic products, and adhesion molecules [29]. Truncated forms of RAGE are described as soluble decoys to prevent ligands from interacting with cell fl-RAGE surface receptor: es-RAGE (an alternative splicing product) and c-RAGE (a cleavage product by metalloproteases). Consequently, s-RAGE indirectly inhibits the fl-RAGE receptor. Thus, an inflammatory reaction mediated by fl-RAGE can be downregulated by these soluble decoys. This anti-inflammatory regulation has been described in bronchi and lungs of smokers, provoked by an underexpression of fl-RAGE with overexpression of es-RAGE isoforms [30, 50]. The inflammatory RAGE pathway is complex and still poorly understood because its activation can induce inflammatory cascades as well as anti-inflammatory retro control by soluble forms.

4.3. Dysregulation of RAGE Pathway in Keratoconus. To our knowledge, our study described for the first time the implication of the RAGE pathway in KC. Results of RT-qPCR showed a significant underexpression of global RAGE transcripts in the corneal epithelium of keratoconus compared to healthy subjects. Nevertheless, this is emphasised by the ratio fl-RAGE/es-RAGE which highlighted a decrease of es-RAGE in KC \((p = 0.01)\). Indeed, we did not observe any difference in fl-RAGE expression in the two groups using RT-qPCR whereas we highlighted a significant under-
expression of es-RAGE in KC compared to controls. The results of Western Blotting showed a significant higher quantity of fl-RAGE protein in the corneal epithelium of KC compared to healthy subjects. These results were confirmed by a significant lower quantity of s-RAGE protein (soluble forms) in tears of KC compared to healthy subjects. As explained above, the RAGE pathway can be implicated in activating inflammatory cascades as well as in an anti-inflammatory retro control, depending on tissues and pathologies [50]. In KC, the RAGE pathway seems to be upregulated in the corneal epithelium without upregulation of soluble decoys in tears. Interestingly, we highlighted a lower expression of RAGE transcripts concerning es-RAGE in KC, which could result from an alternative splicing mechanism. These results were confirmed by RAGE-protein expression with a higher concentration of fl-RAGE in the corneal epithelium of KC and a lower concentration of s-RAGE (considered like decoys) in tears of KC compared with healthy patients. Our study shows that a proinflammatory dysregulation similar to that described for smokers in the lung is present in keratoconic corneas [30, 50]. In normal corneas, the activation of fl-RAGE (transmembrane receptor) can be downregulated by the soluble RAGE decoys while in KC there is an upregulation of the RAGE pathway without retro control of decoys in tears (Figure 5). Thus, the RAGE pathway is dysregulated in KC, potentially generating a number of proinflammatory signals in the ocular surface.

It is worth noting that the majority of KC in our study was grades 1 and 2 in Krumeich severity scale, which are the two lower stages of its ranking. It is possible that the RAGE pathway is present at an earlier stage of KC causing or fuelling the vicious circle of tissue remodelling. The modification of the expression of RAGE in early forms of keratoconus is particularly interesting: RAGE could be an easy access biomarker in tears particularly useful in keratoconus diagnosis. Indeed, KC is difficult to diagnose for nonspecialist ophthalmologists, requiring clinical and topographical evidences. In addition, the need for viable biomarkers in the early stages of KC is particularly interesting in preoperative of refractive surgery (where KC is contraindication) [51]. Further studies are needed to explore the inflammatory pathways resulting in the dysregulation of RAGE in KC and their putative implication in the progression of corneal ectasia. The biomarkers based on the RAGE pathway could become an interesting biological tool to evaluate KC progression. Moreover and interestingly, some blocking peptides like inhibitor ligands named RAP or SAGE and monoclonal specific antibodies anti-RAGE have been used in an attempt to block inflammatory RAGE pathway in different inflammation experimental models [32, 52–56]. The established biomarkers described in this study could also take a place for the future monitoring of RAGE-based therapeutics.

5. Conclusion

To our knowledge, we described for the first time the implication of RAGE pathway in KC. Other studies will compare these results and try to better specify the role that RAGE
plays in KC pathophysiology and determine how the RAGE mRNA and protein isoforms (pro- or anti-inflammatory) could be used as future biomarkers for the diagnosis, prognosis, and treatment of the KC.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| AGEs         | Advanced glycation end products |
| c-DNA        | Complementary-deoxyribonucleic acid |
| C            | Celsius degree |
| c-RAGE       | Cleaved-RAGE |
| DAMPs        | Damage-Associated Molecular Patterns |
| D            | Diopter |
| dNTP         | Deoxyribonucleotide |
| EDTA         | Ethylenediaminetetraacetic acid |
| es-RAGE      | Endogenous secretory-RAGE |
| fl-RAGE      | Full length-RAGE |
| HMGB1        | High-mobility group box 1 |
| IL           | Interleukin |
| KC           | Keratoconus |
| Kmax         | Maximal keratometry |
| ml           | Milliliters |
| MMP          | Matrix metalloproteinase |
| NaCl         | Sodium Chloride |
| OCT          | Optimal cutting temperature compound |
| PBS          | Phosphate-Buffered Saline |
| PRK          | Photorefractive keratotomy |
| RAGE         | Receptor for Advanced Glycation End Products |
| RNA          | Ribonucleic acid |
| RT-qPCR      | Reverse Transcription Quantitative Polymerase Chain Reaction |
| SDS          | Sodium dodecyl sulfate |
| s-RAGE       | Soluble-RAGE |
| TBS          | Tris-Buffered Saline |
| TBST         | TBS and polysorbate 20 (Tween 20) |
| TGF          | Tumoral growth factor |
| TNF          | Tumoral necrosis factor |
| UVA          | Ultraviolet A |

**Data Availability**

All the data used to support the findings of this study are included within the article and figures.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

VN, JM, FC, LB, and VS were responsible for the design and conception of the study. VN and JM collected the samples and performed the laboratory manipulations. VN, JM, LB, and CB analyzed and interpreted data. VN, JM, LB, and CB were in charge of statistical analyses. VN and JM wrote the manuscript. All authors made critical revisions to the article. All authors gave their final approval of the article. Valentin Navel and Jean Malecaze contributed equally.

**Acknowledgments**

The laboratory received funds by Théa Pharma for their research on cornea and RAGE.

**References**

[1] M. L. Khaled, I. Helwa, M. Drewry, M. Seremwe, A. Estes, and Y. Liu, "Molecular and histopathological changes associated with keratoconus," *BioMed Research International*, vol. 2017, 16 pages, 2017.

[2] J. H. Krachmer, R. S. Feder, and M. W. Belin, "Keratoconus and related noninflammatory corneal thinning disorders," *Survey of Ophthalmology*, vol. 28, no. 4, pp. 293–322, 1984.

[3] E. di Martino, M. Ali, and C. F. Inglehearn, "Matrix metalloproteinases in keratoconus--too much of a good thing?," *Experimental Eye Research*, vol. 182, pp. 137–143, 2019.

[4] Y. S. Rabinowitz, "Keratoconus," *Survey of Ophthalmology*, vol. 42, no. 4, pp. 297–319, 1998.

[5] T. T. McMahon, T. B. Edrington, L. Szczotka-Flynn et al., "Longitudinal changes in corneal curvature in keratoconus," *Cornea*, vol. 25, no. 3, pp. 296–305, 2006.

[6] A. N. Jinabhai, "Customised aberration-controlling corrections for keratoconic patients using contact lenses," *Clinical and Experimental Ophthalmology*, vol. 103, no. 1, pp. 31–43, 2019.

[7] A. C. Ferdi, V. Nguyen, D. M. Gore, B. D. Allan, J. J. Rozema, and S. L. Watson, "Keratoconus natural progression," *Ophthalmology*, vol. 126, no. 7, pp. 935–945, 2019.

[8] W. Li and B. Wang, "Efficacy and safety of transepithelial corneal collagen crosslinking surgery versus standard corneal collagen crosslinking surgery for keratoconus: a meta-analysis of randomized controlled trials," *BMC Ophthalmology*, vol. 17, no. 1, 2017.

[9] K. Allard and M. Zetterberg, "Toric IOL implantation in a patient with keratoconus and previous penetrating keratoplasty: a case report and review of literature," *BMC Ophthalmology*, vol. 18, no. 1, 2018.

[10] M. Matthaei, H. Sandhaeger, M. Hermel et al., "Changing indications in penetrating keratoplasty: a systematic review of 34 years of global reporting," *Transplantation*, vol. 101, no. 6, pp. 1387–1399, 2017.

[11] J. S. Parker, K. van Dijk, and G. R. J. Melles, "Treatment options for advanced keratoconus: a review," *Survey of Ophthalmology*, vol. 60, no. 5, pp. 459–480, 2015.

[12] D. A. Godfrooij, G. A. De Wit, C. S. Uiterwaal, S. M. Imhof, and R. P. Wisse, "Age-specific incidence and prevalence of keratoconus: a nationwide registration study," *American Journal of Ophthalmology*, vol. 175, pp. 169–172, 2017.

[13] A. R. Pearson, B. Soneji, N. Sarvananthan, and J. H. Sandford-Smith, "Does ethnic origin influence the incidence or severity of keratoconus?" *Eye*, vol. 14, no. 4, pp. 625–628, 2000.

[14] D. Gatinel, "Eye rubbing, a sine qua non for keratoconus?", *International Journal of Keratoconus and Ectatic Corneal Diseases*, vol. 5, no. 1, pp. 6–12, 2016.

[15] B. Jafari, H. Lichter, and R. D. Stulting, "Asymmetric keratoconus attributed to eye rubbing," *Cornea*, vol. 23, no. 6, pp. 560–564, 2004.

[16] A. M. Bawazeer, "Atopy and keratoconus: a multivariate analysis," *British Journal of Ophthalmology*, vol. 84, no. 8, pp. 834–836, 2000.
Inhibition of the receptor for advanced glycation end-products in acute respiratory distress syndrome: a randomised laboratory trial in pigs, *Scientific Reports*, vol. 9, no. 1, p. 9227, 2019.

[10] Disease Markers

[17] H. Hashemi, S. Heydarian, E. Hooshmand et al., “The prevalence and risk factors for keratoconus: a systematic review and meta-analysis,” *Cornea*, vol. 39, no. 2, pp. 263–270, 2019.

[18] H. Valgaeren, C. Koppen, and G. Van Camp, “A new perspective on the genetics of keratoconus: why have we not been more successful?,” *Ophthalmic Genetics*, vol. 39, no. 2, pp. 158–174, 2018.

[19] K. H. Weed, C. J. MacEwen, and C. N. J. McGhee, “The variable expression of keratoconus within monozygotic twins: Dundee University Scottish Keratoconus Study (DUSKS),” *Contact Lens and Anterior Eye*, vol. 29, no. 3, pp. 123–126, 2006.

[20] J. Wheeler, M. A. Hauser, N. A. Afshari, R. Rand Allingham, K. H. Weed, C. J. MacEwen, and C. N. J. McGhee, “The variable expression of keratoconus within monozygotic twins: Dundee University Scottish Keratoconus Study (DUSKS),” *Contact Lens and Anterior Eye*, vol. 29, no. 3, pp. 123–126, 2006.

[21] V. Galvis, T. Sherwin, A. Tello, J. Merayo, R. Diez–Feijo, “Subclinical keratoconus and inflammatory molecules from tears,” *British Journal of Ophthalmology*, vol. 93, no. 6, pp. 820–824, 2009.

[22] V. Navel, J. Malecaze, B. Pereira et al., “Oxidative and antioxidative stress markers in keratoconus: a systematic review and meta-analysis,” *Acta Ophthalmologica*, vol. 99, no. 6, pp. e777–e794, 2020.

[23] K. Nishtala, N. Pahuja, R. Shetty, R. M. Nuijts, and A. Ghosh, “Tear biomarkers for keratoconus,” *Eye and Vision*, vol. 3, no. 1, 2016.

[24] R. P. L. Wisse, J. J. W. Kuiper, R. Gans, T. R. D. J. Radstake, and A. Van der Lelij, “Cytokine expression in keratoconus and its corneal microenvironment: a systematic review,” *The Ocular Surface*, vol. 13, no. 4, pp. 272–283, 2015.

[25] S. Ahmad, H. Khan, Z. Siddiqui et al., “AGEs, RAGEs and s-RAGE; friend or foe for cancer,” *Seminars in Cancer Biology*, vol. 49, pp. 44–55, 2018.

[26] S. Ahmad, M. Y. Khan, Z. Rafi et al., “Oxidation, glycation and glycoxidation—the vicious cycle and lung cancer,” *Seminars in Cancer Biology*, vol. 49, pp. 29–36, 2018.

[27] S. Tabrez, K. Z. Al-Shali, and S. Ahmad, “Lycopene powers the inhibition of glycation-induced diabetic nephropathy: a novel approach to halt the AGE-RAGE axis menace: lycopene powers the inhibition of glycation-induced DN,” *BioFactors*, vol. 41, no. 5, pp. 372–381, 2015.

[28] A. Bierhaus, P. M. Humphert, M. Morcos et al., “Understanding RAGE, the receptor for advanced glycation end products,” *Journal of Molecular Medicine*, vol. 83, no. 11, pp. 867–886, 2005.

[29] N. Vazzana, F. Santilli, C. Cuccurullo, and G. Davi, “Soluble forms of RAGE in internal medicine,” *Internal and Emergency Medicine*, vol. 4, no. 5, pp. 389–401, 2009.

[30] J. Xie, J. D. Méndez, V. Méndez-Valenzuela, and M. M. Aguilar-Hernández, “Cellular signalling of the receptor for advanced glycation end products (RAGE),” *Cellular Signalling*, vol. 25, no. 11, pp. 2185–2197, 2013.

[31] J. Audard, T. Godet, R. Blondonnet et al., “Inhibition of the receptor for advanced glycation end-products in acute respiratory distress syndrome: a randomised laboratory trial in pigs,” *Scientific Reports*, vol. 9, no. 1, p. 9227, 2019.

[32] T.-W. Lee, Y.-H. Kao, T.-I. Lee, and Y.-J. Chen, “ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes,” *European Journal of Clinical Investigation*, vol. 47, no. 9, pp. 675–683, 2017.

[33] S. J. Park, T. Kleffmann, and P. A. Hessian, “The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the g82s polymorphic variant,” *Journal of Biological Chemistry*, vol. 286, no. 24, pp. 21384–21392, 2011.

[34] C. Gross, C. Belville, M. Lavergne et al., “Advanced glycation end products and receptor (RAGE) promote wound healing of human corneal epithelial cells,” *Investigative Ophthalmology & Visual Science*, vol. 61, no. 3, p. 14, 2020.

[35] M. M. Moschos, I. Chatziralli, A. Sioziou, and M. Gazouli, “Receptor of advanced glycation end products gene polymorphism and primary open-angle glaucoma,” *Ophthalmic Research*, vol. 58, no. 2, pp. 81–84, 2017.

[36] D. Tao, X. Mai, T. Zhang, and Y. Mei, “Association between the RAGE (receptor for advanced glycation end-products) -374T/A gene polymorphism and diabetic retinopathy in T2DM,” *Revista da Associação Médica Brasileira*, vol. 63, no. 11, pp. 971–977, 2017.

[37] J. Xu, L.-J. Chen, Y. Jian et al., “Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy,” *Cellular Physiology and Biochemistry*, vol. 48, no. 2, pp. 705–717, 2018.

[38] W. Yu, J. Yang, W. Sui, Q. Bin, P. Huang, and Y. Chen, “Association of genetic variants in the receptor for advanced glycation end products gene with diabetic retinopathy: a meta-analysis,” *Medicine*, vol. 95, no. 39, article e4463, 2016.

[39] M. Banevicius, A. Vilkcviciute, L. Kriauciuniene, R. Liutkeviciene, and V. P. Deltuva, “The association between variants of receptor for advanced glycation end products (RAGE) gene polymorphisms and age-related macular degeneration,” *Medical Science Monitor*, vol. 24, no. janvier, pp. 190–199, 2018.

[40] Z. Wang, J. T. Handa, W. Richard Green, W. J. Stark, R. S. Weinberg, and S. Albert, “Advanced glycation end products and receptors in Fuchs’ dystrophy corneas undergoing Descemet’s stripping with endothelial keratoplasty,” *Ophthalmology*, vol. 114, no. 8, pp. 1453–1460, 2007.

[41] C. T. Raghavan and R. H. Nagaraj, “AGE-RAGE interaction in the TGFβ2-mediated epithelial to mesenchymal transition of human lens epithelial cells,” *Glycoconjugate Journal*, vol. 33, no. 4, pp. 631–643, 2016.

[42] S. Al-Swailam, X. Zhenhua, W. Lijuan, M. J. Hartsoc, S. C. Yiu, and E. J. Duh, “Induction of endothelial RAGE expression in pterygium,” *Molecular Vision*, vol. 20, pp. 1740–1748, 2014.

[43] K. Nielsen, H. Jhjordal, M. Pihlmann, and T. J. Corydon, “Update on the keratoconus genetics,” *Acta Ophthalmologica*, vol. 91, no. 2, pp. 106–113, 2013.

[44] D. W. Sabiston, E. J. Duh, M. Pihlmann, and T. J. Corydon, “Update on the keratoconus genetics,” *Acta Ophthalmologica*, vol. 91, no. 2, pp. 106–113, 2013.

[45] D. W. Sabiston, E. J. Duh, M. Pihlmann, and T. J. Corydon, “Update on the keratoconus genetics,” *Acta Ophthalmologica*, vol. 91, no. 2, pp. 106–113, 2013.

[46] C. C. Teng, “Electron microscope study of the pathology of keratoconus: part 1A,” *American Journal of Ophthalmology*, vol. 55, no. 1, pp. 18–47, 1963.

[47] Y. S. Rabinowitz, “The genetics of keratoconus,” *Ophthalmology Clinics of North America*, vol. 16, no. 4, pp. 607–620, 2003.
Y. Pouliquen, J. Bureau, M. Mirshahi, S. S. Mirshahi, M. Assouline, and G. Lorens, "Keratoconus and inflammatory processes," *Bulletin De La Societe Belge D'ophtalmologie*, vol. 262, pp. 25–28, 1996.

L. Zhang, M. Bukulin, E. Kojro et al., "Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases," *Journal of Biological Chemistry*, vol. 283, no. 51, pp. 35507–35516, 2008.

A. Faiz, M. van den Berge, C. J. Vermeulen, N. H. T. ten Hacken, V. Guryev, and S. D. Pouwels, "AGER expression and alternative splicing in bronchial biopsies of smokers and never smokers," *Respiratory Research*, vol. 20, no. 1, 2019.

M. W. Belin, H. S. Jang, and B. M. Keratoconus, "Keratoconus: diagnosis and staging," *Cornea*, vol. 41, no. 1, 2021.

R. Blondonnet, J. Audard, C. Belville et al., "RAGE inhibition reduces acute lung injury in mice," *Scientific Reports*, vol. 7, no. 1, p. 7208, 2017.

E. Charrin, C. Faes, A. Sotiaux et al., "Receptor for advanced glycation end products antagonism blunts kidney damage in transgenic Townes sickle mice," *Frontiers in physiology*, vol. 10, p. 880, 2019.

S. Lee, C. Piao, G. Kim, J. Y. Kim, E. Choi, and M. Lee, "Production and application of HMGB1 derived recombinant RAGE-antagonist peptide for anti-inflammatory therapy in acute lung injury," *European Journal of Pharmaceutical Sciences*, vol. 114, pp. 275–284, 2018.

J. B. Lewis, C. Mejia, C. Jordan et al., "Inhibition of the receptor for advanced glycation end-products (RAGE) protects from secondhand smoke (SHS)-induced intrauterine growth restriction IUGR in mice," *Cell and Tissue Research*, vol. 370, no. 3, pp. 513–521, 2017.

H. Yang, H. Liu, Q. Zeng et al., "Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box a, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation," *Molecular Medicine*, vol. 25, no. 1, p. 13, 2019.